Hims & Hers Health (HIMS) Stock Price, News & Analysis

+0.54 (+3.85%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
5.43 million shs
Average Volume
5.28 million shs
Market Capitalization
$3.13 billion
P/E Ratio
Dividend Yield
Price Target

Hims & Hers Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
3.4% Upside
$15.08 Price Target
Short Interest
13.20% of Float Sold Short
Dividend Strength
News Sentiment
0.33mentions of Hims & Hers Health in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$8.34 M Sold Last Quarter
Proj. Earnings Growth
From $0.18 to $0.32 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.49 out of 5 stars

Medical Sector

475th out of 922 stocks

Offices & Clinics Of Medical Doctors Industry

3rd out of 7 stocks

HIMS stock logo

About Hims & Hers Health Stock (NYSE:HIMS)

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.

HIMS Stock Price History

HIMS Stock News Headlines

3 Stocks That Suddenly Drew in Options Traders
Options are complicated and not for the faint of heart. While some investors may use them to take on irresponsible leverage levels on their minor positions, others could use them to express their predictions on a particular stock.
3 Stocks That Suddenly Drew in Options Traders (HIMS)
Three discounted stocks caught the attention of call option buyers last week, and they have Wall Street analysts to back them through double-digit upside.
Hims & Hers Health Stock Could Become a Wealth Compounder
Shares of Hims & Hers Health Inc. NYSE: HIMS are jumping by as much as 15.5% after the company released its first quarter 2024 earnings results. This quarter is arguably the most important quarter as it sets the tone for the rest of the year in any stock.
Hims & Hers Health Stock Could Become a Wealth Compounder (HIMS)
Hims & Hers stock could give investors the best of both stability and double-digit upside through EPS projections and price targets, especially after 1Q24
Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Update
Contrasting Auna (NYSE:AUNA) & Hims & Hers Health (NYSE:HIMS)
Is Hims & Hers Health Stock a Buy?
10 Solid Reasons To Buy Hims & Hers Stock
Hims & Hers Health (NYSE:HIMS) PT Raised to $16.00
See More Headlines
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Offices & clinics of medical doctors
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$872 million
Book Value
$1.60 per share


Free Float
Market Cap
$3.13 billion
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Andrew DudumMr. Andrew Dudum (Age 35)
    Co-Founder, Chairman & CEO
    Comp: $1.7M
  • Mr. Yemi Okupe (Age 38)
    Chief Financial Officer
    Comp: $804.05k
  • Ms. Melissa BairdMs. Melissa Baird (Age 46)
    Chief Operating Officer
    Comp: $917.67k
  • Ms. Irene A. Becklund (Age 39)
    Senior VP, Controller & Principal Accounting Officer
    Comp: $361.12k
  • Ms. Soleil Teubner Boughton (Age 45)
    Chief Legal Officer & Corporate Secretary
    Comp: $782.66k
  • Mr. Mike Chi (Age 43)
    Chief Marketing Officer
    Comp: $514.77k
  • Dr. Patrick Carroll M.D. (Age 66)
    Chief Medical Officer, Member of Medical Advisory Board & Director
    Comp: $27.03k
  • Ms. Khobi Brooklyn
    Chief Communications Officer
  • Ms. Amee Parekh
    Senior Vice President of Human Resources
  • Dr. Peter Stahl M.D.
    Senior VP & Member of Medical Advisory Board

HIMS Stock Analysis - Frequently Asked Questions

Should I buy or sell Hims & Hers Health stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIMS shares.
View HIMS analyst ratings
or view top-rated stocks.

What is Hims & Hers Health's stock price target for 2024?

15 brokerages have issued 12-month price targets for Hims & Hers Health's stock. Their HIMS share price targets range from $10.00 to $20.00. On average, they anticipate the company's share price to reach $15.08 in the next year. This suggests a possible upside of 3.4% from the stock's current price.
View analysts price targets for HIMS
or view top-rated stocks among Wall Street analysts.

How have HIMS shares performed in 2024?

Hims & Hers Health's stock was trading at $8.90 at the beginning of the year. Since then, HIMS shares have increased by 63.8% and is now trading at $14.5750.
View the best growth stocks for 2024 here

Are investors shorting Hims & Hers Health?

Hims & Hers Health saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 18,390,000 shares, an increase of 5.3% from the April 15th total of 17,470,000 shares. Based on an average trading volume of 6,060,000 shares, the short-interest ratio is presently 3.0 days. Approximately 13.2% of the company's shares are short sold.
View Hims & Hers Health's Short Interest

When is Hims & Hers Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our HIMS earnings forecast

How were Hims & Hers Health's earnings last quarter?

Hims & Hers Health, Inc. (NYSE:HIMS) issued its earnings results on Monday, May, 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.03. The company had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative trailing twelve-month return on equity of 0.70% and a negative net margin of 0.24%. Hims & Hers Health's revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.05) earnings per share.

What guidance has Hims & Hers Health issued on next quarter's earnings?

Hims & Hers Health updated its second quarter 2024 earnings guidance on Monday, May, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $292.0 million-$297.0 million, compared to the consensus revenue estimate of $288.1 million.

Who are Hims & Hers Health's major shareholders?

Hims & Hers Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.68%), Institutional Venture Management XVI LLC (2.43%), Institutional Venture Management XV LLC (2.43%), Redpoint Management LLC (2.36%), Mckinley Capital Management LLC (0.30%) and M&G Plc (0.26%). Insiders that own company stock include Alex Bard, Andrew Dudum, Christiane Pendarvis, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee.
View institutional ownership trends

How do I buy shares of Hims & Hers Health?

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:HIMS) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners